Bryn Mawr Capital Management LLC Has $6.58 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Bryn Mawr Capital Management LLC boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1,871.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,659 shares of the medical research company's stock after purchasing an additional 33,850 shares during the period. Bryn Mawr Capital Management LLC owned about 0.07% of Charles River Laboratories International worth $6,583,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. Wellington Management Group LLP increased its stake in shares of Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock worth $736,819,000 after purchasing an additional 3,738,018 shares during the last quarter. Mizuho Securities USA LLC increased its stake in shares of Charles River Laboratories International by 2,336.4% during the 3rd quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company's stock worth $19,081,000 after purchasing an additional 92,895 shares during the last quarter. Premier Fund Managers Ltd increased its stake in shares of Charles River Laboratories International by 56.3% during the 3rd quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company's stock worth $49,573,000 after purchasing an additional 90,000 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after purchasing an additional 85,759 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Charles River Laboratories International by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after purchasing an additional 47,221 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock traded up $0.69 on Friday, reaching $162.94. 771,549 shares of the stock were exchanged, compared to its average volume of 1,045,073. The firm's 50 day moving average is $173.39 and its 200-day moving average is $188.81. Charles River Laboratories International, Inc. has a one year low of $150.79 and a one year high of $275.00. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The firm has a market cap of $8.33 billion, a PE ratio of 1,086.26, a P/E/G ratio of 6.77 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm's quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.46 EPS. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 9.41 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on CRL shares. TD Cowen boosted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research note on Monday, November 11th. Bank of America lowered their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a research note on Friday, December 13th. CLSA lowered shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target on the stock. in a research note on Monday, November 18th. JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research note on Thursday. Finally, The Goldman Sachs Group decreased their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and an average target price of $195.71.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).